HC Wainwright & Co. maintains Tyra Biosciences at Buy, lowers price target to $27 from $29

HC Wainwright & Co. kept its Buy rating on Tyra Biosciences but reduced its price target to $27 from $29, a 6.9% decrease. The new target suggests a 28.6% upside from the Nov 10 close of $21.

Original reporting
Published Nov 11, 2026, 12:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 12:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. maintains Tyra Biosciences at Buy, lowers price target to $27 from $29 — source image
Decision brief

The 30-second read

$TYRABearishMed
01

Why it matters

The downgrade may trigger short‑term selling pressure.

02

Market read

Analyst price‑target cuts are a common catalyst for micro‑cap moves; traders may adjust positions accordingly.

03

What to watch

Upcoming clinical trial data could offset the target reduction.

Relevance 6/10Novelty 7/10Timing: immediate after release

Background

The article reports a recent analyst rating action on Tyra Biosciences.

Company-level read

Ticker impact

$TYRABearishHigh confidence
Context

HC Wainwright lowered its price target on Tyra Biosciences to $27 from $29.

Expected impact

likely downward pressure as the market prices in the lower target

Evidence & confidence

A price‑target cut is a direct negative catalyst, especially for a micro‑cap biotech where analyst opinions move price.

Market effects

May slightly dampen sentiment in the small‑cap biotech sector.

Limited to U.S. biotech investors.

Low

Counterpoint

Some investors may view the cut as an opportunity if they believe the stock is undervalued.

Key entities

  • HC Wainwright & Co.

    Equity research firm that issued the price‑target change.

  • Tyra Biosciences

    Biotech firm whose stock is affected.

Related articles

$TYRAMed

Tyra Biosciences 3Q 2026: EPS ($0.74) — 10-Q Summary

Tyra Biosciences reported a wider net loss in 3Q 2026, with R&D costs rising due to dabogratinib trials and headcount growth. Net loss was $51.12M, and diluted EPS was ($0.74). The company has $700.5M in cash, expected to last through 2030. Dabogratinib trials showed initial positive results.

$TYRAHighAI 8/10

Raymond James reiterates Strong Buy on Tyra Biosciences stock

Raymond James reiterated a Strong Buy rating and $50 price target for Tyra Biosciences (NASDAQ:TYRA) after a discussion with its CEO. The stock trades at $20.93, with analyst targets ranging from $29 to $59. Tyra's lead asset, dabogratinib, showed promising Phase 2 data for non-muscle invasive bladder cancer, with a 100% overall response rate at a 60 mg dose. Raymond James projects $2 billion in combined revenue by 2035 from Tyra's three opportunities.

$TYRAMedAI 8/10

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

Tyra Biosciences (TYRA) reported Phase 2 trial results for dabogratinib, showing a 57% complete response rate in patients with FGFR3-altered bladder cancer. The study met its primary endpoint, with 79% objective response rate. The company plans further enrollment and regulatory discussions for Phase 3 design. Safety data showed no severe adverse events at the 60 mg dose.